Prosthetic joint infections: Update in diagnosis and treatment

Swiss Medical Weekly

Volumn 135, Issue 17-18, 2005, Pages 243-251

  Trampuz, Andrej ^a   Zimmerli, Werner ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

Author keywords

Biofilm; Diagnosis; Prosthetic joint infection; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN; DAPTOMYCIN; FLEROXACIN; FUSIDIC ACID; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; BACTERIUM IDENTIFICATION; BIOFILM; CLINICAL PROTOCOL; DEVICE REMOVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; INFECTION RISK; JOINT PROSTHESIS; KNEE PROSTHESIS; PATHOGENESIS; PEROPERATIVE CARE; PREOPERATIVE EVALUATION; PROSTHESIS FAILURE; PROSTHESIS INFECTION; REVIEW; SURGICAL TECHNIQUE; SYMPTOMATOLOGY;

EID: 20044387266     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Steckelberg JM, Osmon DR. Prosthetic Joint Infection. In: Bisno AL and Waldvogel FA eds. 3rd. Washington, DC: Am Soc Microbiol 2000:173-209.
2. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001;33(Suppl 2):94-106.
3. Hebert CK, Williams RE, Levy RS, Barrack RL. Cost of treating an infected total knee replacement. Clin Orthop 1996; 140-5.
4. Sculco TP. The economic impact of infected total joint arthroplasty. Instr Course Lect 1993;42:349-51.
5. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-54.
6. Pandey R, Berendt AR, Athanasou NA. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues: The OSIRIS Collaborative Study Group. Oxford Skeletal Infection Research and Intervention Service. Arch Orthop Trauma Surg 2000;120:570-4.
7. Segawa H, Tsukayama DT, Kyle RF, Becker DA, Gustilo RB. Infection after total knee arthroplasty: A retrospective study of the treatment of eighty-one infections. J Bone Joint Surg Am 1999;81:1434-45.
8. Brause BD. Infections with prostheses in bones and joints. In: Mandell GL, Bennett JE, and Dolin R eds. 6th. Washington, DC: WB Saunders 2005:1332-7.
9. Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop 2003;414:69-88.
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8.
11. Donlan RM. Biofilms: Microbial life on surfaces. Emerg Infect Dis 2002;8:881-90.
12. Boles BR, Thoendel M, Singh PK. Self-generated diversity produces "insurance effects" in biofilm communities. Proc Natl Acad Sci USA 2004;101:16630-5.
13. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998;280:295-8.
14. Lewis K. Programmed death in bacteria. Microbiol Mol Biol Rev 2000;64:503-14.
15. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284: 1318-22.
16. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001;33: 1567-72.
17. Williams RJ, Henderson B, Sharp LJ, Nair SP. Identification of a fibronectin-binding protein from Staphylococcus epidermidis. Infect Immun 2002;70:6805-10.
18. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982;146:487-97.
19. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection: Evidence for a local granulocyte defect. J Clin Invest 1984;73:1191-200.
20. Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 2004;32:222-8.
21. Laffer R, Graber P, Ochsner P, Zimmerli W. The case for differentiated orthopedic management of prosthetic knee-associated infection. 44th ICAAC, American Society for Microbiology, October 30-November 2, 2004, Washington, DC 2004; Abstract K-113.
22. Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection 2003;31:99-108.
23. Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis 1997;56:470-5.
24. Kadoya Y, Kobayashi A, Ohashi H. Wear and osteolysis in total joint replacements. Acta Orthop Scand Suppl 1998;278:1-16.
25. Bauer TW, Schils J. The pathology of total joint arthroplasty: II: Mechanisms of implant failure. Skeletal Radiol 1999;28: 483-97.
26. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. J Bone Joint Surg Am 1990;72: 878-83.
27. Poss R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop 1984; 117-26.
28. Salvati EA, Robinson RP, Zeno SM, Koslin BL, Brause BD, Wilson PD Jr. Infection rates after 3175 total hip and total knee replacements performed with and without a horizontal unidirectional filtered air-flow system. J Bone Joint Surg Am 1982; 64:525-35.
29. Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: Case-control study. Clin Infect Dis 1998; 27:1247-54.
30. Ainscow DA, Denham RA. The risk of haematogenous infection in total joint replacements. J Bone Joint Surg Br 1984; 66:580-2.
31. Murdoch DR, Roberts SA, Fowler JV Jr, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001;32:647-9.
32. Trampuz A, Steckelberg JM, Osmon DR, Cockerill FR, Hanssen AD, Patel R. Advances in the laboratory diagnosis of prosthetic joint infection. Rev Med Microbiol 2003;14:1-14.
33. McCarty DJ. Synovial fluid. In: Koopman WJ ed. 14. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:83-104.
34. Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. Am J Med 2004;117:556-62.
35. Athanasou NA, Pandey R, de Steiger R, Crook D, Smith PM. Diagnosis of infection by frozen section during revision arthroplasty. J Bone Joint Surg Br 1995;77:28-33.
36. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA 1978;239:2772-5.
37. Hughes JG, Vetter EA, Patel R et al. Culture with BACTEC Peds Plus/F Bottle Compared with Conventional Methods for Detection of Bacteria in Synovial Fluid. J Clin Microbiol 2001;39:4468-71.
38. Atkins BL, Athanasou N, Deeks JJ, et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty: The OSIRIS Collaborative Study Group. J Clin Microbiol 1998;36:2932-9.
39. Spangehl MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am 1999; 81:672-83.
40. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol 1999;37:3281-90.
41. Tigges S, Stiles RG, Roberson JR. Appearance of septic hip prostheses on plain radiographs. AJR Am J Roentgenol 1994; 163:377-80.
42. Corstens FH, van der Meer JW. Nuclear medicines role in infection and inflammation. Lancet 1999;354:765-70.
43. Smith SL, Wastie ML, Forster I. Radionuclide bone scintigraphy in the detection of significant complications after total knee joint replacement. Clin Radiol 2001;56:221-4.
44. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990;162:96-102.
45. Widmer AF, Westner A, Frei R, Zimmerli W. Killing of non-growing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6.
46. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994;33:959-67.
47. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41.
48. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br 2005;87:249-56.
49. Ure KJ, Amstutz HC, Nasser S, Schinalzried TP. Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. J Bone Joint Surg Am 1998;80:961-8.
50. Hope PG, Kristinsson KG, Norman P, Elson RA. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. J Bone Joint Surg Br 1989;71:851-5.
51. Raut W, Siney PD, Wroblewski BM. One-stage revision of infected total hip replacements with discharging sinuses. J Bone Joint Surg Br 1994;76:721-4.
52. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement? J Bone Joint Surg Br 2003; 85:637-40.
53. Westrich GH, Salvati EA, Brause B. Postoperative infection. In: Bono JV, McCarty JC, Thornhill TS, Bierbaum BE, and Turner RH eds. 1st. New York, NY: Springer-Verlag, 1999:371-390.
54. Windsor RE, Insall JN, Urs WK, Miller DV, Brause BD. Two-stage reimplantation for the salvage of total knee arthroplasty complicated by infection. Further follow-up and refinement of indications. J Bone Joint Surg Am 1990;72:272-8.
55. Colyer RA, Capello WN. Surgical treatment of the infected hip implant. Two-stage reimplantation with a one-month interval. Clin Orthop 1994;75-9.
56. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992;14:1251-3.
57. Schwank S, Rajacic Z, Zimmerli W, Blaser J. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998;42:895-8.
58. Shirtliff ME, Calhoun JH, Mader JT. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 2001;48:253-8.
59. Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:1503-9.
60. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000;44: 164-6.
61. Frippiat F, Meunier F, Derue G. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004;54:1158.
62. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-81.
63. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993;37:1214-8.
64. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40.
65. Trampuz A, Zimmerli W. New strategies for the treatment of infections associated with prosthetic joints. Curr Opin Investig Drugs 2005;6:185-90.
66. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42: 3086-91.
67. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000;46: 775-84.
68. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79:1137-44.
69. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31.
70. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996;347:1579-82.
71. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000.